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Purpose: Survivin is one of the apoptosis inhibitor genes and is rarely expressed in adult
tissues. However, survivin expression has been detected in various human cancers and
correlations have been recognized between the level of expression of this gene in tumors
and prognosis. In this study, we investigated the correlations between survivin mRNA expres-
sion in osteosarcoma tissues and clinicopathological parameters.
Methods: There were 22 osteosarcoma patients in our hospital with paraffin-embedded
tissues which could be extracted from biopsy specimens. We used the RT-PCR method
after extracting total RNA and conducted a densitometric analysis to determine the ratio of
survivin relative to h-GAPDH as an internal marker.
Results: Expression of survivin mRNA was detected in all osteosarcoma samples. Patients
with metastasis had high survivin mRNA levels in initial biopsy specimens (p0.01). More-
over, there was a statistically significant difference in survivin mRNA expression between
patients with and without metastasis (p0.01).
Conclusion: We concluded that high levels of survivin mRNA expression suggest poor prog-
nosis for osteosarcoma patients.
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I. Introduction
Osteosarcoma is associated with high morbidity rates
in young adults and adolescents. It is an aggressive tumor
which frequently metastasizes to the lung. Current treatment
protocols for osteosarcoma include wide surgical resection
of the primary lesion and multidrug chemotherapy [4, 19].
Clinically, prognosis is determined postoperatively by the
response to chemotherapy and, in the past, by tumor size and
wide surgical margin. These have long been the only useful
prognostic factors for osteosarcoma patients.
Survivin is a member of the inhibitor of apoptosis pro-
tein (IAP) family and is characterized by a unique structure.
It contains only a single baculovirus inhibitor of apoptosis
protein repeat (BIR) and lacks a carboxy terminal really
interesting new gene (RING) finger domain. It also binds
directly to both caspase-3 and caspase-7, thereby inhibiting
apoptosis [5].
Moreover, survivin is abundantly expressed during
fetal development but not in adult human tissues [3]. Sur-
vivin mRNA has been detected in various human malignant
neoplasms, such as gastric cancer, breast cancer, lung
cancer, colorectal cancer, pancreatic cancer, urinary bladder
cancer, soft tissue sarcoma, neuroblastoma and osteo-
sarcoma. Survivin has thus been thought to promote tumor
progression [12–17, 20, 21, 25, 27].
In this study, we measured survivin expression levels
in paraffin-embedded osteosarcoma tissues, and concluded
that high survivin mRNA expression levels may serve as a
prognostic factor for osteosarcoma patients. Correspondence to: Eiji Osaka, M.D., Department of Orthopaedic
Surgery, Nihon University School of Medicine, 30–1 Oyaguchikami-
machi, Itabashi-ku, Tokyo 173–8610, Japan. 
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II. Material and Methods
Patients and tissue samples
Twenty-two tissue specimens, all obtained from
osteosarcoma patients at the Department of Orthopaedic
Surgery, Nihon University School of Medicine, during the
period from 1992 to 2000, were embedded in paraffin.
The patients were 14 males and eight females, with a mean
age of 25 years (range 8 to 62 years). Twenty patients had
Enneking’s stage IIB, and the remaining two stage IIIB
[9]. The tumors were located on the distal femur in nine
patients, proximal tibia in five patients, proximal fibula
in one patient, proximal humerus in two patients, vertebrae
in two patients and at other sites in three patients. The
histological type of osteosarcoma was osteoblastic in 14
patients, chondroblastic in four patients and fibroblastic in
four patients. Twenty-one patients underwent resection after
the initial biopsy, but one received wide resection as the
initial operation. Following the initial biopsy, 21 patients
received multi-agent neoadjuvant chemotherapy and wide
resection, and eleven cases had metastases. The cytotoxic
drugs used as preoperative chemotherapy were cis-diammine
dichloroplatinum, adriamycin, iphosphamide, and high-dose
methotrexate. Eleven patients had metastases, and 5 years
after the first medical examination, nine patients had died of
their disease, and two patients died of intra- or postoperative
complications (Table 1).
Normal bone, muscle and fat tissue specimens were
obtained from healthy donors who had undergone total knee
arthroplasty. Informed consent was obtained from all sub-
jects prior to conducting the study.
Cell culture
A human osteosarcoma cell line (NOS-1) was obtained
from the Riken Gene Bank, Bioresources Center. The cells
were cultured in RPMI1640 medium supplemented with
10% heat-inactivated fetal bovine serum, 100 U/ml penicil-
lin, and 0.1 mg/ml streptomycin under 5% CO2 at 37C.
RNA isolation
1) Total RNA extraction from paraffin-embedded tissue 
sections
Five sections (each 10 µm thick) were prepared from
paraffin-embedded tumor samples. We isolated RNA from
these samples according to the method used by Stanta and
Schneider [22]. After deparaffinization, RNA lysis buffer
containing 2% SDS, 0.1 mM EDTA, 10 mM Tris-HCl, and
proteinase K (20 mg/ml) was added. The mixture was incu-
bated overnight at 60C. After this incubation, RNA was
extracted with 2 M sodium acetate, phenol and chloroform-
isoamylalcohol (1:24). This mixture was centrifuged at
15,000 rpm for 20 min at 4C. The aqueous supernatant was
transferred to a new microtube and precipitated with an
equal volume of isopropanol and addition of glycogen. After
Table 1. Patient information (1992 to 2000)
Case Age (yr) Sex Site Stage Histology Chemotherapy Metastasis Follow-up 
(months) Outcome
1 17 F Lt. Femur IIB Osteoblastic  106 CDF
2 22 M Lt. Humerus IIB Osteoblastic 72 CDF
3 9 M Rt. Tibia IIB Osteoblastic 61 CDF
4 27 M Lt. Tibia IIB Osteoblastic 38 DOD
5 20 M Rt. 5th Rib IIB Osteoblastic 25 DOD
6 55 F 2, 3rd Lumbar IIB Osteoblastic 35 DOD
7 16 F Rt. Tibia IIB Chondroblastic 79 CDF
8 12 M Lt. Femur IIB Chondroblastic 64 CDF
9 20 M Lt. Fibula IIB Chondroblastic  160 NED
10 62 F Lt. Femur IIB Chondroblastic 73 CDF
11 13 M Lt. Femur IIB Fibroblastic 55 DOD
12 10 M Lt. Tibia IIB Fibroblastic 75 CDF
13 13 F Rt. Femur IIB Fibroblastic 79 CDF
14 41 F Lt. Pelvis IIB Fibroblastic  / 2 DOO*
15 34 M Lt. Tibia IIB Osteoblastic  153 CDF
16 17 M Lt. Humerus IIB Osteoblastic  / 6 DOO**
17 12 F Rt. Femur IIB Osteoblastic 21 DOD
18 13 M Rt. Talus IIB Osteoblastic 57 DOD
19 8 M Lt. Femur IIB Osteoblastic 25 DOD
20 54 F Rt. Femur IIB Osteoblastic 15 DOD
21 13 M Lt. Femur IIIB Osteoblastic 44 DOD
22 60 M 3rd Lumbar IIIB Osteoblastic 62 DOD
CDF, continuous disease free; NED, no evidence of disease; DOD, dead of disease; DOO, dead of other disease; *, intraoperative death;
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the sample had been incubated at 80C for at least 30 min,
RNA was pelleted and washed in 70% ethanol and then
100% ethanol. The pellet was dried and resuspended in TE
buffer.
2) RNA extraction from NOS-1
Total RNA was extracted from the osteosarcoma cell
line NOS-1 with TRIzol reagent (Gibco BAL) by the acid-
guanidium-phenol chloroform method.
Quantification of RNA
The total RNA quantity was determined by ultraviolet
(UV) spectrophotometry using Gene Spec III (Hitachi). We
adjusted the concentration of mRNA to 0.5 g/ml.
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was reverse transcribed to cDNA using a Takara
RNA PCR kit (AMV) Version 3.0 (Takara, Otsu, Japan)
with oligo (dT) as a primer. RT reactions were carried out
at 42C for 30 min, followed by annealing at 99C for 5
min and finally holding at 4C. PCR amplifications were
performed on a Mastercycler (Eppendorf, Westbury, NY,
USA).
To determine the saturation phase of RT-PCR amplifi-
cation, we started with cycle titrations for survivin. Reac-
tions were stopped after 10, 20, 25, 30, 35, 40, 45, 50 and 60
cycles. The PCR cycle number determined for survivin was
35, hence the saturation phase was not reached.
We used human glyceraldehyde-3-phosphate dehydro-
genase (h-GAPDH) as an internal marker and NOS-1 as a
positive control. In paraffin-embedded tissues, PCR prod-
ucts larger than 200 bp were undetectable because of nucleic
acid degradation. We therefore designed primers with less
than 200 bp, and primer pairs for survivin mRNA were as
follows. The sequence of the forward primer for survivin
was 5'-TGCCCCGACGTTGCC-3', and the sequence of the
reverse primer for survivin was 5'-CAGTTCTTGAATGTA-
GAGATGCGGT-3'.
Analysis and quantities of PCR products
PCR products were electrophoresed through 12% poly-
acrylamide gel, because of difficulty obtaining short PCR
products from paraffin-embedded tissues when using
agarose gel. We used Scion Image (Scion Corp., Frederick,
MD) to accurately determine band densities. For each sam-
ple, we determined the survivin/GAPDH mRNA ratio.
Statistical analysis
All statistical analyses were performed using the SPSS
11.0J software package for Windows (SPSS Inc., Chicago,
IL). The differences of survivin mRNA expression with
various clinicopathological parameters were analyzed using
either the Mann-Whitney U test or the Kruskal-Wallis test.
Survival time was calculated as the date of resection until
date of death or date of the latest follow-up. Survival curves
were plotted by the Kaplan-Meier method; statistical differ-
ences were analyzed using the log-rank test. A probability
value less than 0.05 was considered to indicate a statistically
significant difference.
III. Results
RT-PCR was performed to determine the expressions
of survivin mRNA in normal tissues, the osteosarcoma
cell line NOS-1, and clinical samples from osteosarcoma
patients. Survivin mRNA expression was detected in all
osteosarcoma samples but none of the normal tissues. We
used pre-saturation phase PCR amplification cycle numbers
for survivin and GAPDH. This made densitometric evalua-
tion and comparison of mRNA levels among tissue samples
feasible.
Expression of survivin mRNA in normal tissues, NOS-1 and 
clinical samples
No survivin mRNA was detected in normal bone, fat or
muscle tissues, and survivin mRNA expression was detected
in NOS-1 (Fig. 1). Survivin mRNA was detectable in all
osteosarcoma samples, and levels of survivin mRNA were
0.830.25 in initial biopsy samples (Fig. 2). Results are
presented in Table 2.
Correlations among metastatic status, 5 year survival and 
levels of survivin mRNA expression
In patients with metastases, as compared to those with-
out metastases, survivin mRNA levels were higher in both
initial biopsy samples (Fig. 2). Among patients who died
within 5 years of being diagnosed with osteosarcoma, sur-
vivin mRNA levels were also high in both initial biopsy
Fig. 1. Survivin mRNA expressions in normal tissues (bone, fat and
muscle) and the osteosarcoma cell line NOS-1.
Fig. 2. Survivin mRNA expressions in osteosarcoma samples. Fig-
ure shows initial biopsy samples. The numbers below correspond to
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samples. However, there were no statistically significant
relationships with other clinicopathological parameters
(stage, histological type, age, sex and tumor site) (Table 3).
Further, the comparison of stage IIB and IIIB cannot be said
to be entirely reliable due to the small number of patients
involved in IIIB.
Prognostic value of survivin mRNA expression
Survival was assessed in 20 patients (excluding two
patients who died of other diseases) according to the levels
of survivin mRNA expression obtained in their initial biop-
sy. The high expression of a gene is defined as the level
above the median, while the low expression group includes
all cases with levels below the median. The survival of
patients with high survivin expression in the initial biopsy
specimen was significantly poorer than that of those with
low survivin expression, as assessed by Kaplan-Meier
method (p0.05) (Fig. 3).
IV. Discussion
Osteosarcoma is the most common primary malignant
bone tumor in children and adolescents. It is a highly aggres-
sive neoplasm typically composed of spindle cells producing
osteoids. The prognosis for patients with osteosarcoma has
typically been very poor, and clinically has been determined
postoperatively by the response to chemotherapy and, in the
past, by tumor size. These have long been the only useful
prognostic factors for osteosarcoma patients.
Recently, several studies have shown survivin mRNA
expression to be detectable in various human cancers, and
that there are correlations between the expression levels
of this gene and prognosis [12–17, 20, 21, 25, 27]. The
only report on survivin expression in osteosarcoma used
immunohistochemistry. Survivin expression is also report-
edly a useful prognostic marker in osteosarcoma, and patients
showing survivin expression could potentially benefit from
optimal selection of neoadjuvant chemotherapy [25]. In
this study, we demonstrated, for the first time, expressions
of survivin mRNA in paraffin-embedded tumor tissues,
obtained by initial biopsy, using competitive RT-PCR.
Moreover, survivin has been regarded as a novel mem-
ber of the IAP family. Survivin is structurally unique among
mammalian IAPs, containing only a single BIR and lacking
a carboxy terminal RING finger domain. Survivin was
shown to inhibit processing of procaspase-3 and procaspase-
7 and to specifically bind both active caspases in vitro [5,
Table 2. Levels of survivin mRNA expression
Case Survivin/GAPDH
10 . 6 6
20 . 7 3
30 . 7 7
41 . 1 2
50 . 9 1
60 . 9 3
70 . 7 3
80 . 6 4
90 . 6 6
10 0.56
11 1.34
12 0.75
13 0.6
14 0.69
15 0.51
16 1.03
17 1.4
18 1.14
19 0.95
20 0.81
21 0.69
22 0.54
Table 3. Comparison of survivin mRNA levels according to clinico-
pathological parameters
Variables No. of patients p-value
Stage
IIB vs IIIB 20 vs 2 0.17
Histological type
osteoblastic vs chondroblastic vs 
fibroblastic type
14 vs 4 vs 4 0.18
Metastasis
Meta vs Non-meta 11 vs 9 <0.01
Age
20 years vs >20 years 14 vs 8 0.24
Sex
Male vs Female 14 vs 8 0.62
Tumor development area
upper extremity vs lower extremity 
vs others
2 vs 14 vs 6 0.58
5 year survival
alive vs dead 11 vs 9 <0.01
Differences were analyzed using either the Mann-Whitney U test or
the Kruskal-Wallis test. Probability values less than 0.05 were con-
sidered to indicate a statistically significant difference.
Fig. 3. Prognostic values of survivin mRNA expressions; survivin
in initial biopsy samples (excluding DOO in 2 patients).Survivin Expression in Osteosarcoma 99
24]. Remarkably, caspase-3 plays a key role in promoting
the apoptosis signal [6].
It has recently become possible to isolate RNA from
formalin-fixed paraffin-embedded tissue and to perform RT-
PCR using this RNA [10, 22]. In fact, several reports have
described gene analyses using RNA extracted from paraffin-
embedded tissues from retinoblastoma [22], Ewing’s sar-
coma [2, 18], small round-cell tumor [7], synovial sarcoma
[26], liposarcoma [11], rhabdomyosarcoma [8] and colon
cancer [23]. Abrahamsen et al. [1] described quantitative
analysis of mRNA in archived and routine diagnostic tissues
as being possible for melanoma.
We analyzed survivin mRNA expression levels using
the RT-PCR method. As to osteosarcoma, high expression
of survivin mRNA in initial biopsy samples was especially
common in cases with metastases. In the initial biopsy sam-
ples from patients who died within 5 years, levels of expres-
sion of this gene were high. Moreover, the 5 year survival
rate was much lower in the high expression than in the low
expression group (Fig. 3). Our results do not conflict with
those of previous studies [12–17, 20, 21, 25, 27]. In spite of
their small size, osteosarcoma in patients with high survivin
mRNA expression may be rapidly growing and metastasiz-
ing with increased resistance to chemotherapeutic regimens.
We conclude that survivin levels in initial biopsy sam-
ples are useful prognostic indicators, that can be used not
only to determine whether this gene is expressed or not, but
also the level of expression, using paraffin-embedded tis-
sues. Our findings raise the possibility of performing retro-
spective molecular profiling, at the mRNA level, of archived
tissues employing a routine diagnostic technique.
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